Darzalex
Johnson & Johnson’s Darzalex and Spravato Achieve Milestones: Darzalex Leads Sales, Spravato Surpasses $1 Billion Revenue
Johnson & Johnson, Darzalex, Spravato, Pharmaceutical Sales, Multiple Myeloma, Depression Treatment, Revenue Milestones
ICER Report Highlights Unjustified Price Hikes on Five Brand-Name Drugs, Costing U.S. $815 Million in 2023
ICER, unsupported price increases, drug price hikes, pharmaceutical companies, Gilead Sciences, Johnson & Johnson, Novartis, Biktarvy, Darzalex, Entresto, Cabometyx, Xeljanz.
GSK’s Blenrep Demonstrates Survival Advantage Over J&J’s Darzalex in Multiple Myeloma Treatment
GSK, Blenrep, Belantamab mafodotin, Multiple myeloma, DREAMM-7, DREAMM-8, Darzalex, Survival advantage, Regulatory challenges
Johnson & Johnson’s Oncology Segment Thrives with Darzalex and Carvykti, Offsetting Stelara Decline
Johnson & Johnson, Darzalex, Carvykti, Stelara, Oncology, Multiple Myeloma, Pharmaceutical Sales
GSK Strengthens Case for Blenrep’s Return in Multiple Myeloma Treatment
Blenrep, GSK, multiple myeloma, ASCO, DREAMM-8, DREAMM-7, Velcade, Darzalex, Pomalyst, CAR-T therapy, antibody-drug conjugate